Why the study?
A lack of direct comparisons between different antihypertensive drugs precluded evaluating their relative efficacy in reversing left ventricular hypertrophy in hypertensive patients.
Does the type of antihypertensive drug affect the efficacy of reversing left ventricular hypertrophy in hypertensive patients?
Does the type of antihypertensive drug affect the efficacy of reversing left ventricular hypertrophy in hypertensive patients?
This protocol outlines a planned systematic review and meta-analysis to evaluate the comparative efficacy of various antihypertensive drug classes in reversing left ventricular hypertrophy.
Protocol for comparing antihypertensive classes on LVH reversal; leaves open optimal regimen pending completed meta-analysis.
BACKGROUND: Reversing left ventricular hypertrophy (LVH) can reduce the incidence of adverse cardiovascular events. The lack of direct comparison between different antihypertensive drugs cannot evaluate the superiority-inferiority differentiation of different antihypertensive drugs in reversing LVH. Therefore, the objective of this protocol for systematic review and meta-analysis was to compare the efficacy of different types of antihypertensive drugs in reversing LVH in hypertensive patients. METHODS: This meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement guidelines. Studies were identified through systematic searches in June 2021 with no restrictions on date and time, language, and publication status using the following bibliographic databases: Embase, Medline, PubMed, Web of Science, Science Direct, and the Cochrane Library. The risk of bias assessment of the included studies was performed by two authors independently using the tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). All calculations were carried out with Stata 11.0 (The Cochrane Collaboration, Oxford, United Kingdom). RESULTS: The results of this systematic review and meta-analysis will be published in a peer-reviewed journal. CONCLUSION: We hypothesized that the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in antihypertensive therapy could achieve better efficacy in reversing LVH in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: